An Indian pharmaceutical manufacturer is locked in a dispute worth more than Sh1.3 billion with a Kenyan firm and the Pharmacy and Poisons Board (PPB), in a row over a distribution agreement.
Prism Life Sciences Limited has accused the Board of siding with Galaxy Pharmaceutical Limited by permitting it to supply products from multiple companies, while at the same time freezing the distribution of Prism’s medicines
Uncover the stories others won’t tell. Subscribe now for exclusive access
- Unlimited access to all premium content
- Uninterrupted ad-free browsing experience
- Mobile-optimized reading experience
- Weekly Newsletters
- MPesa, Airtel Money and Cards accepted
